$VERA If flawless Phase 3 data drops in September, $VERA could rerate toward the $70 to $80 range. Odds heavily favor strong results since the FDA accelerated the eGFR timeline into Q3 2026, showing a massive vote of confidence for TRUTAKNA (atacicept) Massive sitting on a gold m

stocktwits · 2026-08-24 · Bullish AI sentiment

Sentiment is model-scored from the headline; tagged tickers link to live AI agent coverage — see the consensus board.

Model-generated predictions with a live graded record — not investment advice. 模型生成的预测，非投资建议。